Posted on December 7, 2011 by Sitemaster
So a meta-analysis of data from multiple clinical trials has now shown rigorously something that we did, in fact, already know … that there was no excess incidence of cardiovascular mortality associated with androgen deprivation therapy (ADT) in clinical trials conducted to date in which use of ADT was compared to a placebo. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, cardiovascular, meta-analysis, mortality, risk | 2 Comments »
Posted on November 3, 2011 by Sitemaster
The big news today is the publication, in The Lancet, of the interim results of the NCIC CTG PR.3/MRC UK PR07 trial, originally presented by Warde et al. at the annual meeting of the American Society for Clinical Oncology in June 2010 and then by Mason et al. at the annual meeting of the American Society for Radiation Oncology (ASTRO) that September. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", ADT, androgen deprivation therapy, EBRT, external beam radiation therapy, localized, locally advanced | Leave a comment »
Posted on August 29, 2011 by Sitemaster
Clinical guidelines issued by the National Comprehensive Cancer Network recommend that prostate cancer patients being treated with androgen deprivation therapy (ADT) — either alone or in combination with radiation therapy — should be screened for osteoporosis and treatment to prevent deterioration of bone health associated with a decline in bone mineral density. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, DXA, fracture, FRAX, guideline, osteopenia, osteoporesis, Prevention | 4 Comments »
Posted on July 19, 2011 by Sitemaster
The addition of androgen deprivation therapy (ADT) to radiation therapy for men with localized prostate cancer is common. It may be used to reduce the size of the prostate prior to brachytherapy or for longer periods in men with higher risk disease to extend survival (which has been demonstrated in large-scale, randomized, multi-center clinical trials). … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: ADT, androgen deprivation therapy, brachytherapy, cardiovascular disease, history, mortality, radiation, risk | 4 Comments »
Posted on May 10, 2011 by Sitemaster
Back in June 2010, we reported on the initial results of SWOG 9921 — a trial that randomized 983 men with high-risk features at prostatectomy to receive adjuvant therapy with androgen deprivation (ADT) alone or in combination with mitoxantrone chemotherapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", adjuvant, ADT, androgen deprivation therapy, surgery | 6 Comments »
Posted on May 9, 2011 by Sitemaster
GTx, Inc. has announced this morning that the company is planning a Phase IIb clinical trial of its oral, selective estrogen receptor agonist (GTx-758, also known as Capesaris™) as a potential first-line treatment for advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Uncategorized | Tagged: androgen deprivation therapy, Capesaris, GTx-758 | 2 Comments »
Posted on April 16, 2011 by Sitemaster
Researchers at Johns Hopkins have attempted to correlate data on PSA doubling time (PSADT) with data on prostate cancer progression in men being treated with intermittent androgen deprivation therapy (IADT) after biochemical recurrence of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: androgen deprivation therapy, doubling time, IADT, intermittent, PSA, PSADT | 1 Comment »
Posted on February 15, 2011 by Sitemaster
It has been suspected for many years that intermittent androgen deprivation (ADT) might have the same or a better impact on survival of prostate cancer patients as continuous ADT, with potentially superior effects on other factors such as quality of life. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, continuous, intermittent, randomized | 2 Comments »
Posted on January 17, 2011 by Sitemaster
A group of French researchers have tested use of a diet and exercise tool-kit for men about to start androgen deprivation therapy (ADT). We have not seen the tool-kit, and obviously it is in French … however, it seems to have met with considerable approval from patients and their doctors. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: ADT, androgen deprivation therapy, diet, education, exercise, tool-kit | Leave a comment »
Posted on December 28, 2010 by Sitemaster
The proposed list of complications as a consequence of androgen deprivation therapy (ADT) for advanced prostate cancer has just been increased. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, age, androgen deprivation therapy, cataracts, risk | Leave a comment »
Posted on December 26, 2010 by Sitemaster
A few weeks ago, a Letter to the Editor in the New England Journal of Medicine focused on the significance of castrate levels of serum testosterone (serum T) in men being treated with LHRH agonists for advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, serum, survival, T, testosterone | 3 Comments »
Posted on November 7, 2010 by Sitemaster
Could serum testosterone levels predict the effectiveness of combined androgen deprivation (ADT2) — through addition of an antiandrogen — in men with progressive prostate cancer and a rising PSA on LHRH agonist therapy alone? … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: ADT, ADT2, androgen deprivation therapy, outcome, progression, survival | Leave a comment »
Posted on November 3, 2010 by Sitemaster
Two new studies just posted on line in the Journal of Clinical Oncology specifically address some of the adverse effects associated with 12 months of continuous androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, adverse effects, androgen deprivation therapy, cognitive, function, physicial | 9 Comments »
Posted on October 27, 2010 by Sitemaster
As we reported at the time, at the annual meeting of the American Society for Clinical Oncology, in June this year, Warde et al. presented the initial survival data from a large, multi-center trial of androgen deprivation therapy (ADT) + radiation compared to ADT alone for patients with high-risk, localized prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: "high risk", ADT, androgen deprivation therapy, localized, radiation | Leave a comment »
Posted on October 23, 2010 by Sitemaster
Metabolic syndrome has been implicated in the development of prostate cancer, but there have been no published data on whether it affects the effectiveness of androgen deprivation therapy (ADT). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, metabolic syndrome, outcome, survival | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 